See more : Hennessy Capital Investment Corp. V (HCIC) Income Statement Analysis – Financial Results
Complete financial analysis of Cutia Therapeutics (2487.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cutia Therapeutics, a leading company in the Biotechnology industry within the Healthcare sector.
- Danske Invest Global Indeks (DKIGIADKKH.CO) Income Statement Analysis – Financial Results
- EnLink Midstream, LLC (ENLC) Income Statement Analysis – Financial Results
- Sunstone Hotel Investors, Inc. (SHO-PH) Income Statement Analysis – Financial Results
- Kuros Biosciences AG (0RHR.L) Income Statement Analysis – Financial Results
- Seaport Calibre Materials Acquisition Corp. (SCMAU) Income Statement Analysis – Financial Results
Cutia Therapeutics (2487.HK)
About Cutia Therapeutics
Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company was incorporated in 2019 and is based in Shanghai, China with additional offices in Beijing, Wuxi and Hong Kong.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 137.62M | 11.37M | 2.04M |
| Cost of Revenue | 66.62M | 3.43M | 428.00K |
| Gross Profit | 71.01M | 7.94M | 1.61M |
| Gross Profit Ratio | 51.60% | 69.84% | 79.00% |
| Research & Development | 215.71M | 180.76M | 110.56M |
| General & Administrative | 46.86M | 12.72M | 12.37M |
| Selling & Marketing | 208.31M | 23.09M | 4.19M |
| SG&A | 255.16M | 35.81M | 16.55M |
| Other Expenses | -399.87M | -326.68M | -120.27M |
| Operating Expenses | 71.01M | 310.89M | 178.41M |
| Cost & Expenses | 677.28M | 314.32M | 178.84M |
| Interest Income | 23.41M | 17.37M | 6.11M |
| Interest Expense | 4.48M | 1.73M | 559.00K |
| Depreciation & Amortization | 42.48M | 18.92M | 9.79M |
| EBITDA | -1.92B | -535.19M | -309.23M |
| EBITDA Ratio | -1,392.79% | -4,569.42% | -14,925.91% |
| Operating Income | -539.65M | -538.28M | -313.98M |
| Operating Income Ratio | -392.12% | -4,735.88% | -15,406.43% |
| Total Other Income/Expenses | -1.42B | -246.63M | -139.60M |
| Income Before Tax | -1.96B | -555.84M | -319.58M |
| Income Before Tax Ratio | -1,426.91% | -4,890.34% | -15,681.11% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 |
| Net Income | -1.96B | -555.84M | -319.58M |
| Net Income Ratio | -1,426.91% | -4,890.34% | -15,681.11% |
| EPS | -9.60 | -6.94 | -3.99 |
| EPS Diluted | -9.60 | -6.94 | -3.99 |
| Weighted Avg Shares Out | 204.61M | 80.05M | 80.05M |
| Weighted Avg Shares Out (Dil) | 204.61M | 80.05M | 80.05M |
Source: https://incomestatements.info
Category: Stock Reports